Oct 2 (Reuters) - Antisense Therapeutics Ltd ANP.AX :
* Advised by FDA that full clinical hold for phase IIb clinical study of ATL1102 for multiple sclerosis has been lifted
* Co's application to conduct clinical trial of ATL1102 has been approved by Human Research Ethics Committee